35 results about "Lanthionine" patented technology

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs. This includes but it is not limited to abscisic acid (ABA), ABA analogs, benzimidazophenyls, repurposed drugs or drug combinations, including thiazolidinediones (TZDs); naturally occurring compounds such as conjugated diene fatty acids, conjugated triene fatty acids, isoprenoids, and natural and synthetic agonists of peroxisome proliferator-activated receptors that activate this receptor through an alternative mechanism of action involving LANCL2 or other membrane proteins to treat or prevent the common inflammatory pathogenesis underlying type 2 diabetes, atherosclerosis, cancer, some inflammatory infectious diseases such as influenza and autoimmune diseases including but not limited to inflammatory bowel disease (Crohn's disease and Ulcerative colitis), rheumatoid arthritis, multiple sclerosis and type 1 diabetes and other chronic inflammatory conditions.

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

Disclosed are lanthionine bridged peptides having the structuremethods of their preparation and their use as pharmacologically active agents.

The present invention relates to microorganisms and processes for the efficient preparation of L-amino acids such as L-methionine. In particular, the present invention relates to microorganisms and processes in which the formation and / or accumulation of homolanthionine in the methionine pathway is reduced and / or prevented.

The present invention relates generally to the fields of medicine and pharmacy. More specifically, it relates to novel galanin analogs and their use in therapy. The present invention provides cyclic peptide analogs of galanin, wherein the galanin analog comprises a (methyl)lanthionine bridge, and wherein the analog has the general formula "X1-X2-X3-X4-X5-X6- X7‑X8‑X9‑X10‑X11‑X12‑X13‑X14‑X15‑X16‑X17‑X18‑X19‑X20‑X21‑X22‑", or its lack of X1 and / or up to 11 C-terminal residues A truncated variant wherein two residues selected from X3, X4, X6, X7, X10 and X13-X19 together form a lanthionine bridge of the structure Ala-S-Ala or the structure Abu-S-Ala or Ala ‑S‑Abu's methyllanthionine bridge.

A hair straightening composition comprising: i) gamma- thiobutyrolactone; ii) an acid or salt thereof; and iii) an amine. A method for lanthionizing keratin fibres to achieve relaxation of said keratin fibres in which said composition is applied to the hair.

Provided are compounds of Formula (I):The compounds target the lanthionine synthetase C-like (LANCL) family of proteins, including LANCL2 and LANCL3. The compounds can be used to treat conditions such as inflammatory diseases, metabolic diseases, autoimmune diseases, cancers, and infectious diseases. Exemplary conditions include inflammatory conditions of the liver, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis; inflammatory conditions of the bile duct, such as primary biliary cholangitis, primary sclerosing cholangitis; inflammatory bowel disease, such as Crohn's disease and ulcerative colitis; lupus, such as systemic lupus erythematosus, lupus nephritis, and cutaneous lupus; arthritis, such as rheumatoid arthritis; hyperglycemia, such as type 1 diabetes, type 2 diabetes, and prediabetes and associated conditions such as atherosclerosis and diabetic kidney disease; psoriasis; and multiple sclerosis.

To search a number of variation compounds having a CaSR agonist activity in order to obtain a substance having a more excellent kokumi-imparting function, and more particularly to provide a kokumi-imparting agent, which contains the foregoing substance, and a composite kokumi-imparting agent, which likewise contains the aforementioned substance and another substance having a CaSR agonist activity as well, in combination a kokumi-imparting agent comprises a lanthionine derivative and a composite kokumi-imparting agent comprising the lanthionine derivative and another substance having a CaSR agonist activity.

The present invention provides a pharmaceutical composition consisting of: a first pharmaceutically active part consisting of one or more cannabinoids; a second pharmaceutically active part consisting of one or more of glutathione, cysteine, acetylcysteine, alliin, briximine, carboxy methylcysteine, mucine, cat urine, lantidine, mesine hydrochloride, penicillamine cysteine disulfide, or any functional equivalent thereof; and a pharmaceutical composition comprising the first pharmaceutically active part and the second pharmaceutically active part, wherein the second pharmaceutically active part consists of one or more of glutathione, cysteine, acetylcysteine, alliin, briximine, carboxy methylcysteine, mucine, cat urine, lantidine, mesine hydrochloride, penicillamine cysteine disulfide or any functional equivalent thereof. And optionally one or more excipients; wherein the molar ratio of the second pharmaceutically active moiety to the first pharmaceutically active moiety is at least 0.5: 1, advantageously at least 1: 1. The composition of the present invention is advantageous in that it can prevent hepatotoxicity that may be caused by ingestion of isolated cannabinoids. The present invention also provides a method of manufacturing a pharmaceutical composition comprising the steps of: extracting a first fraction comprising one or more cannabinoids from cannabis plant material using a polar solvent; extracting a second fraction comprising glutathione from the same cannabis plant material using water; and drying and combining the first fraction and the second fraction to form the pharmaceutical composition.

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including autoimmune diseases, inflammatory diseases, chronic inflammatory diseases, diabetes, and infectious diseases, such as lupus, Sjögren's syndrome, rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, viral diseases, and nonalcoholic steatohepatitis. The compounds can also be used to generate cells, such as immune cells, for treating the conditions.